Last Updated : April 23, 2024
Details
Generic Name:
ciltacabtagene autoleucel
Project Status:
Received
Therapeutic Area:
Relapsed or refractory multiple myeloma
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Carvykti
Project Line:
Reimbursement Review
Project Number:
PG0361-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with multiple myeloma who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with multiple myeloma who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 06, 2024 |
|---|---|
| Call for patient/clinician input closed | April 30, 2024 |
| Submission received | April 18, 2024 |
| Submission accepted | - |
Last Updated : April 23, 2024